DFN-02 Open Label Safety Study in Patients With Acute Migraine
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2017
At a glance
- Drugs DFN 02 (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors Dr Reddys Laboratories
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Mar 2016 as per ClinicalTrials.gov record.
- 18 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.